Previous 10 | Next 10 |
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination ‒ Observed plasma SAM reduction in each of the first two dose escalation cohorts of the IDE397 Phase 1 clinical trial, satisfying the clinical p...
IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company co...
IDEAYA Biosciences (IDYA): Q1 GAAP EPS of -$0.28 beats by $0.01.Revenue of $7.2M misses by $0.28M.Cash, cash equivalents and marketable securities of $310.4MPress Release For further details see: IDEAYA Biosciences EPS beats by $0.01, misses on revenue
IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort - Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of ...
IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of initial dose escalation cohort of the Phase 1 clinical trial evaluating IDE397, a potential best-in-class MAT2A inhibitor for MTAP-deletion patients -...
IDEAYA to Participate in Upcoming May 2021 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to ...
IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 PR Newswire SOUTH SAN FRANCISCO, Calif. , April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision...
IDEAYA Biosciences (IDYA) announces clinical data from ongoing Phase 1/2 trial evaluating darovasertib (IDE196) monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma ((MUM)) and Skin Melanoma.Darovasertib monotherapy preliminary res...
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma - Darovasertib monotherapy results in 57% 1-year Overall Survival (OS) Rate in predominantly 2L / 3L and heavily pr...
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...